Abstract

Various neurological manifestations associated with COVID-19 have been detected, and its incidence has been increasing. Neurological symptoms in COVID-19 patients have been determined by 36.4% and were common with severe infection. In literature, neuroleptic malignant syndrome relevant to patients with COVID-19 has been reported very few.

Keywords

neuroleptic malignant syndrome, COVID-19, pandemic